

## SUPPLEMENTAL MATERIAL

**Table S1. Association between patient characteristics and maternal outcome (any adverse event) for the first pregnancy**

Factor	N	Maternal outcome		Odds ratio (95% CI) Adverse event (any)
		No adverse event N (%)	Adverse event (any) N (%)	
<i>Maternal age at conception</i>				
18-30	19	17 (89)	2 (11)	<b>1.16 (0.17 – 7.73)</b>
31 or above	25	22 (88)	3 (12)	
<i>BMI at conception</i>				
<25	20	18 (90)	2 (10)	<b>3.00 (0.34 – 26.19)</b>
25 or above	8	6 (75)	2 (25)	
<i>Treatment prior to conception<sup>1</sup></i>				
No	26	22 (85)	4 (15)	<b>0.32 (0.03 – 3.17)</b>
Yes	18	17 (94)	1 (16)	
<i>Portal hypertension<sup>2</sup></i>				
No	7	5 (71)	2 (29)	<b>0.22 (0.03 – 1.66)</b>
Yes	37	34 (92)	3 (8)	
<i>Oesophageal varices<sup>2</sup></i>				
No	28	25 (89)	3 (11)	<b>1.19 (0.18 – 8.00)</b>
Yes	16	14 (88)	2 (12)	
<i>Antiphospholipid syndrome</i>				
No	40	36 (90)	4 (10)	<b>3.00 (0.25 – 36.11)</b>
Yes	4	3 (75)	1 (25)	
<i>Inherited thrombophilia</i>				
No	35	30 (86)	5 (14)	<b>0.29 (0.01 – 5.78)</b>
Yes	9	9/9 (100)	0 (0)	
<i>Myeloproliferative neoplasms</i>				
No	36	32 (89)	4 (11)	<b>1.14 (0.11 – 11.85)</b>
Yes	8	7 (88)	1 (12)	
<i>Anticoagulation in pregnancy</i>				
No	7	6 (86)	1 (14)	<b>0.71 (0.07 – 7.45)</b>
Yes	38	34 (89)	4 (11)	

Abbreviations: BMI, body mass index; N, number; CI, confidence interval

<sup>1</sup> Treatment prior to the first pregnancy included angioplasty (N=1), endoscopic variceal ligation (N=9), portosystemic shunt (N=6) and stenting of the inferior vena cava (N=2)

<sup>2</sup> Portal hypertension and/or oesophageal varices were present prior to the first conception.

**Table S2. Association between patient characteristics and foetal outcome for the first pregnancy**

Factor	N	Foetal outcome		Odds ratio (95% CI) Pregnancy loss
		Live birth N (%)	Pregnancy loss N (%)	
<i>Maternal age at conception</i>				
18-30	19	13 (68)	6 (32)	<b>0.52 (0.13 – 2.04)</b>
31 or above	26	21 (81)	5 (19)	
<i>BMI at conception</i>				
<25	19	16 (84)	3 (16)	<b>4.27 (0.70 – 25.88)</b>
25 or above	9	5 (56)	4 (44)	
<i>Treatment prior to conception<sup>1</sup></i>				
No	28	23 (82)	5 (18)	<b>2.51 (0.63 – 10.05)</b>
Yes	17	11 (65)	6 (35)	
<i>Portal hypertension<sup>2</sup></i>				
No	8	7 (88)	1 (12)	<b>2.59 (0.28 -23.81)</b>
Yes	37	27 (73)	10 (27)	
<i>Oesophageal varices<sup>2</sup></i>				
No	29	22 (76)	7 (24)	<b>1.05 (0.25 – 4.32)</b>
Yes	16	12 (75)	4 (25)	
<i>Antiphospholipid syndrome</i>				
No	39	30 (77)	9 (23)	<b>3.33 (0.41 – 27.13)</b>
Yes	4	2 (50)	2 (50)	
<i>Inherited thrombophilia</i>				
No	34	25 (74)	9 (26)	<b>0.79 (0.14 – 4.55)</b>
Yes	9	7 (78)	2 (22)	
<i>Myeloproliferative neoplasms</i>				
No	36	27 (75)	9 (25)	<b>1.20 (0.20 – 7.30)</b>
Yes	7	5 (71)	2 (29)	
<i>Anticoagulation in pregnancy</i>				
No	7	6 (86)	1 (14)	<b>2.14 (0.23 – 20.06)</b>
Yes	38	28 (74)	10 (26)	

Abbreviations: N, number; BMI, body mass index; CI, confidence interval.

<sup>1</sup> Treatment prior to the first pregnancy included angioplasty (N=1), endoscopic variceal ligation (N=9), portosystemic shunt (N=6) and stenting of the inferior vena cava (N=2)

<sup>2</sup> Portal hypertension and/or oesophageal varices were present prior to the first conception.